Oncolytic parvoviruses as cancer therapeutics

Abstract The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In pa...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine & growth factor reviews 2010-04, Vol.21 (2), p.185-195
Main Authors: Rommelaere, Jean, Geletneky, Karsten, Angelova, Assia L, Daeffler, Laurent, Dinsart, Christiane, Kiprianova, Irina, Schlehofer, Joerg R, Raykov, Zahari
Format: Article
Language:English
Subjects:
Adenocarcinoma
Advanced Basic Science
Animals
Cancer immunotherapy
Cancer virotherapy
Clinical trial
Clinical Trials as Topic
Humans
Immunologic Factors
Immunomodulation
Life Sciences
Microbiology and Parasitology
Neoplasms
Oncolysis
Oncolytic Virotherapy
Oncolytic Viruses
Oncosuppression
Parvovirus
Parvoviruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In particular, wild-type parvovirus H-1PV can achieve a complete cure of various tumors in animal models and kill tumor cells that resist conventional anticancer treatments. There is growing evidence that H-1PV oncosuppression involves an immune component in addition to the direct viral oncolytic effect. This article summarizes the recent assessment of H-1PV antineoplastic activity in glioma, pancreatic ductal adenocarcinoma, and non-Hodgkin lymphoma models, laying the foundation for the present launch of a first phase I/IIa clinical trial on glioma patients.
ISSN:1359-6101
DOI:10.1016/j.cytogfr.2010.02.011